I know a few people who have had Provenge. It’s good to have it when your PSA is still low. It is hoped that will give extra time. Actual results are a little hard to estimate.

In the IMPACT clinical trial, Provenge extended the median overall survival of men with metastatic castration-resistant prostate cancer (mCRPC) by 4.1 months compared to placebo. The median survival in the Provenge group was 25.8 months versus 21.7 months in the control group.